Home / Drug shortages / Imipenem and Cilastatin Injection

Imipenem and Cilastatin Injection — FDA Drug Shortage

To Be Discontinued — Merck Sharp & Dohme Corp.

The FDA lists a drug shortage record for Imipenem and Cilastatin Injection (injection) from Merck Sharp & Dohme Corp. with status To Be Discontinued. The shortage was first posted on 01/08/2026.

Shortage Details

Status
To Be Discontinued
Company
Merck Sharp & Dohme Corp.
Package NDC
0006-3516-59
Dosage Form
Injection
Presentation
Primaxin, Injection, 500mg (NDC 0006-3516-59)
Initial Posting
01/08/2026
Revised Date

FDA data resources